Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Naïve Subjects

NCT01335711 is registered in ClinicalTrials.gov with ChronTech Pharma AB as lead sponsor.

NCT NCT01335711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01335711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Naïve Subjects
Lead sponsor
ChronTech Pharma AB
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2011
Completion date
June 30, 2012
Enrollment
32 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c